New developments and approaches in the platinum arena

Drugs

Volumn 59, Issue SUPPL. 4, 2000, Pages 29-36

  Judson, Ian ^a   Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; BBR 3464; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; FLUOROURACIL; FOLINIC ACID; LIPOSOMAL CISPLATIN; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; SATRAPLATIN; TETRAPLATIN; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DYSESTHESIA; ENDOMETRIUM CANCER; FACE; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; UROTHELIUM;

ARENA;

EID: 0034117210     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059004-00004     Document Type: Review

References (46)

1. Wiltshaw E, Carr B. Cis-platinum(II)diammine-dichloride. In: Connors TA, Roberts JJ, editors. Platinum coordination complexes in cancer chemotherapy. Heidelberg: Springer-Verlag, 1974: 178-82
2. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-22
3. Aabo K, Adnitt P, Adams M, et al. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 1991; 303: 884-93
4. Kelland LR. Preclinical perspectives on platinum resistance. Drugs 2000; 59 Suppl. 4: 1-8
5. Rowinsky EK, Donehower RC. The clinical pharmacology of paclitaxel (TAXOL). Semin Oncol 1992; 20 Suppl. 3: 16-25
6. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6
7. Stuart G, Bertelsen K, Mangioni C, et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NO-COVA, NCIC CTG and Scottish Intergroup Trial [abstract 1394]. Proc Am Soc Clin Oncol 1998; 17
8. Adams M, Calvert AH, Carmichael J, et al. Chemotherapy for ovarian cancer - a consensus statement on standard practice. Br J Cancer 1998; 78: 1404-6
9. du Bois A, Nitz U, Schroder W, et al. Cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line chemotherapy in ovarian cancer: interim analysis of an AGO Study Group trial [abstract 1272], 33rd Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver, 357a
10. Neijt JP, Hansen M, Hansen SW, et al. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin [abstract 1259]. 33rd Annual Meeting, American Society of Clinical Oncology; 1997 May 17-20; Denver, 352a
11. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998; 25: 340-8
12. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 1998; 16: 255-60
13. Vasuratna A, Kudelka AP, Edwards CL, et al. Prolonged remission of endometrial cancer wth paclitaxel and carboplatin. Anticancer Drugs 1998; 9: 283-5
14. Mangioni C, Landoni F, Colombo A, et al. Concurrent platinum-based chemo- and radiotherapy for locally advanced cervical cancer: a new gold-standard treatment? Ann Oncol 1999; 10 (6): 647-8
15. National Cancer Institute. Clinical announcement: concurrent chemoradiation for cervical cancer [online]. National Cancer Institute, 2000 Feb 24. Available from: URL: http://cancertrials.nci.nih.gov/types/cervical/announcement/index.h tml [Accessed 2000 Mar 27]
16. Burchenal JH, Iranai G, Kern K. et al. 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Recent Results Cancer Res 1980; 74: 146-55
17. Figg WD, Christian MC, Lush R, et al. Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin. Biopharm Drug Dispos 1997; 18: 347-59
18. O'Rourke TJ, Weiss RB, New P, et al. Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). Anticancer Drugs 1994; 5: 520-6
19. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol 1996; 52: 1855-65
20. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998; 16: 2739-44
21. Levi FA, Zidani R, Vannetzel J-M, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst USA 1994; 86: 1608-17
22. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47
23. de Gramont A, Figer A, Seymour M, et al. A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC) [abstract no. 985]. Proc Am Soc Clin Oncol 1998; 17: 257a
24. Machover D, Diaz-Rubio E, Gramont A, et al. Two consecutive phase II trials of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-8
25. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9 (10): 1053-71
26. Kelland LR, Jones M, Abel G, et al. Human ovarian carcinoma cell lines and companion xenografts: a disease oriented approach to new platinum anticancer drug development. Cancer Chemother Pharmacol 1992; 30: 43-50
27. Mistry P, Kelland LR, Abel G, et al. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991; 64: 215-20
28. Holford J, Raynaud F, Murrer BA, et al. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex cis-[amminedichloro(2-methylpyridine)] platinum (II) (AMD473). Anticancer Drug Des 1998; 13: 1-8
29. Holford J, Sharp SY, Murrer BA, et al. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998; 77: 366-73
30. Kelland LR, Sharp SY, O'Neill CF, et al. Discovery and development of platinum complexes designed to circumvent cisplatin resistance. J Inorg Biochem 1999; 77: 111-5
31. Raynaud FI, Boxall FE, Goddard PM, et al. Cis-amminedichloro(2-methylpyridine) platinum (II) (AMD473), a novel sterically hindered platinum complex: In vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res 1997; 3: 2063-74
32. Trigo JM, Beale P, Judson IR, et al. Phase I and pharmacokinetic (PK) study of Cis-amminedichloro(2-methylpyridine) platinum (II) (ZD0473), a novel sterically hindered platinum complex, in patients (pts) with advanced solid malignancies [abstract no. 648m]. 35th Annual Meeting, American Society of Clinical Oncology; 1999 May 15-18; Atlanta, 169a
33. Pratesi G, Perego P, Polizzi D, et al. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer 1999; 80: 1912-9
34. Brabec V, Kasparkova J, Vrana O, et al. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochemistry 1999; 38: 6781-90
35. Manzotti C, Pratesi G, Menta E, et al. BBR3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res. In press
36. Perego P, Caserini C, Gatti L, et al. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol 1999; 55: 528-34
37. Calvert PM, Highley MS, Hughes AN, et al. A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors [abstract/poster no. 333]. Clin Cancer Res 1999; 5
38. Sessa C, Capri G, Gianni L, et al. A phase I with accelerated titration design (ATD) and pharmacokinetic (PK) study of BBR3464, a novel cationic triplatinum complex [abstract 613]. Clin Cancer Res 1999; 5
39. Akaza H, Togashi M, Nishio Y, et al. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 1992; 31: 187-92
40. Judson I, Cerny T, Epelbaum R, et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997; 8 (6): 604-6
41. Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of Bis-acetato-ammine-dichloro cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 1993; 53: 2581-6
42. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997; 15: 2691-700
43. McKeage MJ, Mistry P, Ward J, et al. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 1995; 36 (6): 451-8
44. Beale P, Raynaud F, Hanwell J, et al. Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998; 42 (2): 142-8
45. Newman MS, Colbern GT, Working PK, et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999; 43: 1-7
46. Kelland LR, Barnard CFJ, Mellish KJ, et al. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res 1994; 54: 5618-22